BUFFALO BIOLABS, LLC

Biotech · Private

SA702 vaccine adjuvant combining entolimod (TLR5 agonist) and Alum to enhance potency of inactivated polio vaccine

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Total capital
$2.6M
Federal grants
$581K
2 awards · 2016–2017
Rank in peer group#196 of 502
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
$2M
4 awards · Health and Human S
Rank in Biotech#136 of 4373
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20092011201320152017FEDERAL ↑EQUITY ↓Cumulative $2.6M$149K$150K$1.5M$200K$288K$293K
20092011201320152017FEDERAL ↑EQUITY ↓Cumulative $2.6M$1.5M$200K$288K$293K

Latest events

  • Federal grantHealth and Human S · Phase I · A Novel TLR5 Agonist-Based Adjuvant for Poliovirus Vaccine$293K
  • Federal grantHealth and Human S · Phase I · A Novel TLR5 Agonist-Based Adjuvant for Poliovirus Vaccine$288K
  • Federal contractHealth and Human S · Igf::ot::igf Other Functions R&d - Medical Biomedical (basic Research)$200K
  • Federal contractHealth and Human S · TAS::75 0849::TAS SBIR Topic 255 Phase II Development Of Anticancer Agents$1.5M
  • Federal contractHealth and Human S · Physical Sciences (basic)$150K
  • Federal contractHealth and Human S · Biomedical (basic)$149K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

  • Federal grants#196 · top 39%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • Vector Biomed Inc.Similar federal contract value in Biotech · $2.2M in contracts
  • MerusSimilar federal contract value in Biotech · $2.1M in contracts
  • GENCIRQ, INC.Similar federal contract value in Biotech · $2M in contracts
  • PEARL BIO, INC.Similar federal contract value in Biotech · $1.9M in contracts
  • GLYCAN THERAPEUTICS CORPORATIONSimilar federal contract value in Biotech · $1.9M in contracts
  • NAVIPOINT GENOMICS LLCSimilar federal contract value in Biotech · $1.9M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .